ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1308

Predictors of Interstitial Lung Disease Progression in Patients with Rheumatoid Arthritis

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1220

Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1499

Predictors of Proteinuria Flares in Biopsy Positive Lupus Nephritis

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1009

Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1177

Pregnancy Outcomes in Women with Familial Mediterranean Fever Treated with Anakinra: A Retrospective Study

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1226

Preliminary Findings in the Validation of the Modified Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1346

Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1532

Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0948

Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease

(0934–0954) Systemic Lupus Erythematosus – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 1502

Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1471

Prevalence and Clinical Outcomes of Hemophagocytic Lymphohistiocytosis in Systemic Lupus Erythematosus: A Multi-Institutional Cohort Study

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1492

Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1196

Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1378

Prevalence of Central Nervous System Manifestations in Sjögren’s Disease

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1615

Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis

(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].